The aim of this study is to describe the characteristics and treatment patterns in patients with relapse remitting Multiple Sclerosis in Israel treated with Dimethyl Fumarate

Trial Profile

The aim of this study is to describe the characteristics and treatment patterns in patients with relapse remitting Multiple Sclerosis in Israel treated with Dimethyl Fumarate

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 May 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2017 New trial record
    • 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top